GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Earnings per Share (Diluted)

Clal Biotechnology Industries (XTAE:CBI) Earnings per Share (Diluted) : ₪-0.18 (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Earnings per Share (Diluted)?

Clal Biotechnology Industries's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was ₪0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.18.

Clal Biotechnology Industries's EPS (Basic) for the three months ended in Dec. 2023 was ₪0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.18.

Clal Biotechnology Industries's EPS without NRI for the three months ended in Dec. 2023 was ₪0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.30.

During the past 13 years, Clal Biotechnology Industries's highest 3-Year average EPS without NRI Growth Rate was 54.50% per year. The lowest was -43.90% per year. And the median was 9.30% per year.


Clal Biotechnology Industries Earnings per Share (Diluted) Historical Data

The historical data trend for Clal Biotechnology Industries's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Earnings per Share (Diluted) Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.96 0.68 -0.57 -0.39 -0.20

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.14 -0.04 - -

Competitive Comparison of Clal Biotechnology Industries's Earnings per Share (Diluted)

For the Biotechnology subindustry, Clal Biotechnology Industries's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's PE Ratio distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's PE Ratio falls into.



Clal Biotechnology Industries Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Clal Biotechnology Industries's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-31.051-0)/156.846
=-0.20

Clal Biotechnology Industries's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(0-0)/156.846
=0.00

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Clal Biotechnology Industries  (XTAE:CBI) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Clal Biotechnology Industries Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

Seeking Value in the Construction Industry

By Mark Yu Mark Yu 07-03-2017

McDermott Awarded Paraxylene (pX) Technology Contract in China

By PRNewswire PRNewswire 06-13-2019

Arnold Van Den Berg Keeps Buying Chicago Bridge and Iron Company

By Ashish Sharma Lalitsharma 05-26-2015

Richard Snow Increases His Stake in Chicago Bridge and Iron

By Ashish Sharma Lalitsharma 09-14-2015

CBI: Former Buffett Stock Worth Buying Now

By Jonathan Poland Jonathan Poland 06-29-2017

Does the Increase in Volatility Signal a Dangerous Market Environment?

By Chuck Carnevale Chuck Carnevale 11-11-2016